Saviximab - Shaperon
Alternative Names: Saviximab®Latest Information Update: 07 Feb 2025
At a glance
- Originator Shaperon
- Class Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 22 Oct 2024 Preclinical trials in COVID-2019 infections in South Korea (IV) (Shaperon Pipeline, October 2024)